[Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population].

• DOI: 10.3779/j.issn.1009-3419.2019.09.02
• Publication Date: 2019-09-20
• Authors: Noorwati Sutandyo; Arif Riswahyudi H...; Mulawarman Jayusman
• Keywords: Afatinib

EGFR-tyrosine kinase inhibitors (EGFR-TKIs) were used to treat non-small cell lung cancer (NSCLC) patients with EGFR mutation positive. This study aims compare the effectiveness of first line TKIs; gefitinib, erlotinib, and afatinib in treatment advanced stage NSCLC positive Indonesian population.A retrospective cohort 88 treated gefitinib (n=59), erlotinib (n=22), (n=7) was performed national hospital Indonesia.Inclusion criteria IIIb or IV adenocarcinoma subtype. Subjects less than 18 years a history other malignancy excluded. Outcomes response, progression-free survival (PFS), mortality rate.Complete partial stable disease shown 1.1%, 35.2%, 31.8% subjects, respectively. There subjects developed progressive during treatment. Regarding profile, total 56.8% had deletion exon 19, 42% 21, rare found 3.4% subjects. Demography clinical characteristics no significant association risk disease. The median PFS 11 months (95%CI: 6.8-15.2 months). statistical difference between groups. CONCLUSIONS: Gefitinib, have similar Afatinib tends be associated longer but further investigation is required.